Previous 10 | Next 10 |
home / stock / azncf / azncf news
AstraZeneca's operating income was $2,808 million in Q1 2022, up 49.5% QoQ. At the end of June 2022, the CHMP recommended the approval of Enhertu and Lynparza in the EU. Tagrisso sales were $1,304 million in Q1 2022, up 13.5% year-over-year. The total debt/EBITDA ratio decreas...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. We are closely watching corporate results to determine the near-term outlook for international equities. How co...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...
Pfizer's revenue was $25,661 million in Q1 2022, up 76.8% year-over-year. Pfizer's total debt was $36,441 million in Q1 2022, down 12% from the previous quarter. Over the past 12 months, Pfizer has acquired Biohaven Pharmaceuticals and Arena Pharmaceuticals, which has significantl...
At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
BDJ’s yield is quite high as compared to average income funds, and a minimum positive price growth will generate double-digit returns. Due to its deep diversification, BDJ is in a position to absorb the sectorial risks that have begun due to economic uncertainty. Due to a h...
Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...